pertuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 4957 380610-27-5

Description:

MoleculeDescription

Synonyms:

  • pertuzumab
  • perjeta
  • rhuMAb 2C4
a humanized HER-2 monoclonal antibody; prevents ERBB2 receptor protein from binding (dimerizing) to other receptors in the HER family
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 8, 2012 FDA GENENTECH
March 4, 2013 EMA
June 28, 2013 PMDA Chugai Pharmaceutical

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1178.64 18.28 1839 38149 586637 49978499
Ejection fraction decreased 860.85 18.28 376 39612 18144 50546992
Myelosuppression 629.84 18.28 275 39713 13242 50551894
Neuropathy peripheral 508.23 18.28 495 39493 96262 50468874
Febrile neutropenia 433.02 18.28 456 39532 97211 50467925
Polyneuropathy 420.69 18.28 201 39787 11930 50553206
Metastases to central nervous system 406.73 18.28 192 39796 11090 50554046
Disease progression 354.44 18.28 407 39581 95459 50469677
Mucosal inflammation 300.52 18.28 251 39737 39891 50525245
Cardiotoxicity 292.00 18.28 132 39856 6895 50558241
Neutropenia 284.35 18.28 457 39531 147508 50417628
Drug ineffective 212.67 18.28 202 39786 819131 49746005
Chills 202.67 18.28 311 39677 96376 50468760
Interstitial lung disease 188.29 18.28 221 39767 52955 50512181
Palmar-plantar erythrodysaesthesia syndrome 185.16 18.28 142 39846 19956 50545180
Peripheral sensory neuropathy 174.62 18.28 91 39897 6500 50558636
Left ventricular dysfunction 159.77 18.28 101 39887 10405 50554731
Neutropenic sepsis 150.53 18.28 109 39879 14038 50551098
Rheumatoid arthritis 145.43 18.28 3 39985 202547 50362589
Skin toxicity 124.04 18.28 61 39927 3852 50561284
Joint swelling 122.17 18.28 23 39965 245263 50319873
Pneumonitis 122.04 18.28 133 39855 29377 50535759
Fall 120.69 18.28 57 39931 334875 50230261
Epistaxis 120.47 18.28 196 39792 63758 50501378
Product dose omission issue 120.39 18.28 6 39982 183832 50381304
Stomatitis 118.49 18.28 253 39735 101091 50464045
Drug hypersensitivity 113.95 18.28 29 39959 250981 50314155
Metastases to lung 112.91 18.28 83 39905 10937 50554199
Cardiac dysfunction 110.86 18.28 44 39944 1657 50563479
Arthropathy 110.78 18.28 3 39985 157903 50407233
Vascular device infection 106.13 18.28 57 39931 4327 50560809
Off label use 98.58 18.28 676 39312 473750 50091386
Abdominal discomfort 97.28 18.28 31 39957 231610 50333526
Metastases to bone 95.95 18.28 93 39895 17902 50547234
Nail toxicity 93.16 18.28 26 39962 314 50564822
Onycholysis 92.34 18.28 36 39952 1292 50563844
Hypokalaemia 89.69 18.28 208 39780 87784 50477352
Breast cancer recurrent 87.97 18.28 48 39940 3760 50561376
Therapeutic product effect decreased 87.30 18.28 5 39983 136045 50429091
Pleural effusion 86.84 18.28 196 39792 81258 50483878
Metastases to liver 85.54 18.28 92 39896 20012 50545124
Dysgeusia 85.41 18.28 128 39860 38788 50526348
Drug interaction 83.30 18.28 27 39961 199594 50365542
Systemic lupus erythematosus 82.20 18.28 8 39980 140614 50424522
Decreased appetite 81.96 18.28 345 39643 200578 50364558
Exposure during pregnancy 79.03 18.28 4 39984 121011 50444125
Nail dystrophy 78.41 18.28 28 39960 783 50564353
Condition aggravated 76.80 18.28 73 39915 296985 50268151
Metastasis 76.54 18.28 46 39942 4329 50560807
Bone pain 76.02 18.28 135 39853 47094 50518042
Cardiac failure 75.57 18.28 178 39810 75862 50489274
Cardiomyopathy 74.67 18.28 76 39912 15510 50549626
Metastases to lymph nodes 74.44 18.28 54 39934 6970 50558166
Vomiting 74.42 18.28 619 39369 460139 50104997
Pain 74.20 18.28 224 39764 578679 49986457
Nail discolouration 72.54 18.28 36 39952 2318 50562818
Musculoskeletal stiffness 68.45 18.28 10 39978 128471 50436665
Lacrimation increased 67.49 18.28 75 39913 16917 50548219
Nail disorder 67.04 18.28 58 39930 9650 50555486
Neoplasm progression 66.99 18.28 98 39890 29059 50536077
Sinusitis 66.14 18.28 26 39962 170532 50394604
Lymphoedema 66.05 18.28 56 39932 9066 50556070
Device related infection 63.29 18.28 80 39908 20655 50544481
Injection site pain 63.11 18.28 7 39981 111017 50454119
Radiation skin injury 62.15 18.28 24 39964 839 50564297
Erysipelas 61.52 18.28 47 39941 6561 50558575
Drug intolerance 58.77 18.28 52 39936 219052 50346084
Cellulitis 58.01 18.28 154 39834 70644 50494492
Neurotoxicity 56.72 18.28 64 39924 14676 50550460
Hepatic enzyme increased 56.54 18.28 19 39969 137361 50427775
Tonsillar disorder 54.59 18.28 23 39965 1011 50564125
Discomfort 52.14 18.28 11 39977 108369 50456767
Breast pain 51.94 18.28 45 39943 7499 50557637
Treatment failure 51.70 18.28 22 39966 137615 50427521
Fatigue 51.29 18.28 813 39175 706788 49858348
Tumour pain 50.75 18.28 23 39965 1207 50563929
Colitis 50.63 18.28 101 39887 38428 50526708
Constipation 50.50 18.28 284 39704 185424 50379712
Nausea 50.19 18.28 808 39180 704590 49860546
Confusional state 50.00 18.28 44 39944 185884 50379252
Excessive eye blinking 49.80 18.28 21 39967 925 50564211
Cystitis noninfective 49.39 18.28 20 39968 794 50564342
Pyrexia 48.62 18.28 486 39502 379717 50185419
Dyspnoea 47.79 18.28 650 39338 546958 50018178
Anaemia 47.67 18.28 352 39636 252104 50313032
Somnolence 47.62 18.28 32 39956 154953 50410183
Dehydration 47.47 18.28 242 39746 152207 50412929
Swelling 46.64 18.28 54 39934 200818 50364318
Paronychia 45.90 18.28 34 39954 4530 50560606
Hypertransaminasaemia 45.81 18.28 31 39957 3580 50561556
Hyperpyrexia 45.57 18.28 29 39959 3020 50562116
Metastases to skin 45.15 18.28 22 39966 1361 50563775
Mastitis 44.51 18.28 26 39962 2321 50562815
Hyperfibrinogenaemia 44.18 18.28 9 39979 22 50565114
Weight increased 44.00 18.28 57 39931 201834 50363302
Mastectomy 43.89 18.28 22 39966 1447 50563689
Arthritis 43.39 18.28 8 39980 86713 50478423
Nail infection 43.09 18.28 24 39964 1957 50563179
Alopecia 42.52 18.28 335 39653 244712 50320424
Red cell distribution width increased 41.48 18.28 42 39946 8517 50556619
Systolic dysfunction 40.93 18.28 21 39967 1451 50563685
Gastrointestinal toxicity 40.78 18.28 32 39956 4645 50560491
Haematotoxicity 40.58 18.28 40 39948 7855 50557281
Pseudocirrhosis 40.02 18.28 16 39972 614 50564522
Breast cancer metastatic 39.88 18.28 45 39943 10319 50554817
Gait disturbance 39.72 18.28 36 39952 149969 50415167
Onychalgia 39.70 18.28 17 39971 778 50564358
Inappropriate schedule of product administration 39.65 18.28 5 39983 71826 50493310
Onychomadesis 39.33 18.28 28 39960 3508 50561628
Dry skin 38.50 18.28 97 39891 43094 50522042
Aortitis 38.19 18.28 17 39971 855 50564281
Wound 38.01 18.28 18 39970 105776 50459360
Onychoclasis 37.82 18.28 32 39956 5164 50559972
Pericarditis 37.81 18.28 8 39980 78681 50486455
Chest discomfort 37.55 18.28 159 39829 92563 50472573
Blood creatine increased 37.44 18.28 31 39957 4856 50560280
Osteoarthritis 37.33 18.28 5 39983 68601 50496535
Nasal disorder 37.13 18.28 23 39965 2285 50562851
Product use issue 37.10 18.28 38 39950 149437 50415699
Maternal exposure during pregnancy 37.03 18.28 43 39945 159735 50405401
Vessel puncture site bruise 36.94 18.28 13 39975 348 50564788
Dyschezia 36.92 18.28 21 39967 1783 50563353
Glossodynia 36.67 18.28 23 39965 115546 50449590
Drug abuse 36.04 18.28 3 39985 59843 50505293
Toxicity to various agents 35.92 18.28 71 39917 212428 50352708
Meibomian gland dysfunction 35.81 18.28 10 39978 121 50565015
Product use in unapproved indication 35.45 18.28 24 39964 115795 50449341
Biliary sepsis 35.40 18.28 16 39972 834 50564302
Therapeutic product effect incomplete 35.37 18.28 14 39974 91501 50473635
Madarosis 34.94 18.28 23 39965 2537 50562599
Mobility decreased 34.78 18.28 10 39978 79938 50485198
Hot flush 34.08 18.28 94 39894 44075 50521061
Asthma 33.98 18.28 14 39974 89323 50475813
Acute interstitial pneumonitis 33.36 18.28 14 39974 609 50564527
Suicidal ideation 32.75 18.28 3 39985 55382 50509754
Neutrophil count decreased 32.63 18.28 95 39893 45931 50519205
Breast inflammation 32.00 18.28 9 39979 112 50565024
Impaired healing 31.73 18.28 8 39980 69778 50495358
Malignant neoplasm progression 31.71 18.28 122 39866 68002 50497134
Breast neoplasm 31.58 18.28 17 39971 1296 50563840
Vascular fragility 31.22 18.28 9 39979 123 50565013
Feeling abnormal 31.03 18.28 32 39956 125460 50439676
Folate deficiency 30.23 18.28 19 39969 1936 50563200
Bradycardia 30.04 18.28 7 39981 64419 50500717
General physical health deterioration 29.38 18.28 203 39785 142231 50422905
Post-traumatic pain 29.03 18.28 11 39977 365 50564771
Paraesthesia 28.84 18.28 178 39810 120065 50445071
Hypothalamo-pituitary disorder 28.83 18.28 13 39975 674 50564462
Lower respiratory tract infection 28.82 18.28 150 39838 95051 50470085
Radiation pneumonitis 28.56 18.28 16 39972 1319 50563817
Alopecia areata 28.20 18.28 16 39972 1352 50563784
Depression 28.18 18.28 55 39933 165368 50399768
Flushing 27.97 18.28 116 39872 66899 50498237
Infusion related reaction 27.84 18.28 229 39759 169328 50395808
Enterocolitis 27.84 18.28 30 39958 6537 50558599
Nail bed bleeding 27.82 18.28 10 39978 285 50564851
Blood magnesium decreased 27.81 18.28 39 39949 11121 50554015
Contusion 27.29 18.28 29 39959 112154 50452982
Arthralgia 27.29 18.28 219 39769 438483 50126653
Enterocolitis infectious 27.05 18.28 16 39972 1462 50563674
Mucosal dryness 26.56 18.28 19 39969 2398 50562738
Radiation necrosis 26.35 18.28 10 39978 333 50564803
Axillary pain 26.02 18.28 16 39972 1568 50563568
Pituitary tumour 25.98 18.28 13 39975 852 50564284
Osteitis condensans 25.97 18.28 6 39982 31 50565105
Sarcoid-like reaction 25.95 18.28 5 39983 8 50565128
Rectal haemorrhage 25.82 18.28 78 39910 38480 50526656
Bone marrow failure 25.63 18.28 63 39925 27561 50537575
Depressed level of consciousness 25.54 18.28 5 39983 51948 50513188
Dermatitis acneiform 25.53 18.28 23 39965 4034 50561102
Rash 25.50 18.28 486 39502 436985 50128151
Metastases to soft tissue 25.31 18.28 8 39980 152 50564984
White blood cell count abnormal 25.10 18.28 26 39962 5414 50559722
Vaginal prolapse 25.06 18.28 10 39978 382 50564754
Catheter site pain 25.01 18.28 22 39966 3740 50561396
Skin infection 24.94 18.28 39 39949 12252 50552884
Hair colour changes 24.53 18.28 19 39969 2705 50562431
Rhinorrhoea 24.51 18.28 93 39895 51490 50513646
Adverse event 24.26 18.28 3 39985 43760 50521376
Autonomic neuropathy 24.04 18.28 13 39975 1000 50564136
Pulmonary embolism 24.03 18.28 150 39838 101554 50463582
Hyperchlorhydria 24.00 18.28 15 39973 1513 50563623
Osteonecrosis of jaw 23.88 18.28 68 39920 32458 50532678
Keratitis 23.85 18.28 18 39970 2467 50562669
Pneumonitis chemical 23.83 18.28 8 39980 185 50564951
Injury 23.45 18.28 5 39983 48920 50516216
Mucosal disorder 23.40 18.28 16 39972 1879 50563257
Duodenal ulcer perforation 23.26 18.28 4 39984 45607 50519529
Paralysis recurrent laryngeal nerve 23.19 18.28 6 39982 53 50565083
Hypoaesthesia 23.15 18.28 176 39812 127081 50438055
Incorrect dose administered 23.10 18.28 5 39983 48409 50516727
Mean platelet volume decreased 23.01 18.28 15 39973 1627 50563509
Overdose 22.92 18.28 27 39961 99700 50465436
Secondary cerebellar degeneration 22.90 18.28 6 39982 56 50565080
Odynophagia 22.84 18.28 27 39961 6505 50558631
Hypoglycaemia 22.76 18.28 7 39981 53574 50511562
Therapy partial responder 22.65 18.28 27 39961 6564 50558572
Anxiety 22.42 18.28 69 39919 177537 50387599
Dysuria 22.32 18.28 61 39927 28443 50536693
Tongue coated 22.10 18.28 13 39975 1176 50563960
Hallucination 21.89 18.28 5 39983 46652 50518484
Perforation 21.85 18.28 12 39976 952 50564184
Wheezing 21.61 18.28 11 39977 62036 50503100
Blood glucose increased 21.53 18.28 15 39973 71309 50493827
Gastritis 21.41 18.28 66 39922 32917 50532219
Cardio-respiratory arrest 21.22 18.28 8 39980 53884 50511252
Nodular regenerative hyperplasia 21.15 18.28 8 39980 264 50564872
Nasal congestion 21.14 18.28 7 39981 51113 50514023
Hyperkalaemia 20.94 18.28 6 39982 48083 50517053
Rhabdomyolysis 20.86 18.28 3 39985 39024 50526112
Mitral valve incompetence 20.82 18.28 44 39944 17427 50547709
Myocardial infarction 20.57 18.28 24 39964 89003 50476133
Osteosclerosis 20.54 18.28 19 39969 3448 50561688
Retracted nipple 20.54 18.28 4 39984 7 50565129
Delirium 20.26 18.28 3 39985 38189 50526947
Breast disorder 20.19 18.28 15 39973 2007 50563129
Dandy-Walker syndrome 20.18 18.28 6 39982 92 50565044
Subcutaneous abscess 20.16 18.28 22 39966 4860 50560276
Ventricular hypokinesia 20.15 18.28 20 39968 3960 50561176
Abdominal rigidity 20.13 18.28 14 39974 1690 50563446
Electrocardiogram QT prolonged 19.94 18.28 8 39980 51878 50513258
Coma 19.93 18.28 10 39978 56869 50508267
Blister 19.76 18.28 23 39965 85395 50479741
Metastases to spine 19.72 18.28 17 39971 2814 50562322
Hair texture abnormal 19.68 18.28 19 39969 3637 50561499
Appendiceal abscess 19.59 18.28 7 39981 196 50564940
Vagus nerve disorder 19.55 18.28 6 39982 103 50565033
Rash follicular 19.45 18.28 5 39983 43 50565093
Axillary vein thrombosis 19.42 18.28 8 39980 332 50564804
Agitation 19.29 18.28 9 39979 53375 50511761
Pericardial effusion 19.28 18.28 54 39934 25535 50539601
Osteolysis 19.13 18.28 16 39972 2541 50562595
Gastrointestinal haemorrhage 18.92 18.28 18 39970 73303 50491833
Palmar erythema 18.84 18.28 13 39975 1550 50563586
Pleural disorder 18.74 18.28 9 39979 539 50564597
Tachycardia 18.71 18.28 139 39849 99624 50465512
Opsoclonus myoclonus 18.55 18.28 6 39982 123 50565013
Oxygen saturation decreased 18.55 18.28 110 39878 73138 50491998
Borrelia infection 18.37 18.28 6 39982 127 50565009
Corneal disorder 18.37 18.28 13 39975 1613 50563523
Myalgia 18.34 18.28 164 39824 124155 50440981

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Carbohydrate antigen 15-3 increased 65.93 52.32 9 822 69 29573627
Tidal volume decreased 63.00 52.32 8 823 32 29573664

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 884.13 18.70 1467 33321 721237 63742707
Ejection fraction decreased 593.99 18.70 296 34492 28411 64435533
Myelosuppression 496.73 18.70 247 34541 23583 64440361
Neuropathy peripheral 413.06 18.70 406 34382 117119 64346825
Polyneuropathy 327.47 18.70 176 34612 19718 64444226
Metastases to central nervous system 301.10 18.70 148 34640 13764 64450180
Febrile neutropenia 274.64 18.70 416 34372 187241 64276703
Mucosal inflammation 211.75 18.70 212 34576 62372 64401572
Disease progression 206.98 18.70 314 34474 141366 64322578
Cardiotoxicity 192.07 18.70 99 34689 10175 64453769
Neutropenia 177.68 18.70 396 34392 239228 64224716
Drug ineffective 175.35 18.70 120 34668 840127 63623817
Chills 153.94 18.70 270 34518 136994 64326950
Peripheral sensory neuropathy 147.27 18.70 86 34702 11292 64452652
Neutropenic sepsis 141.46 18.70 110 34678 23162 64440782
Alopecia 136.61 18.70 286 34502 165404 64298540
Stomatitis 128.60 18.70 220 34568 109385 64354559
Left ventricular dysfunction 125.04 18.70 90 34698 16864 64447080
Palmar-plantar erythrodysaesthesia syndrome 118.97 18.70 109 34679 28710 64435234
Metastases to bone 118.60 18.70 94 34694 20341 64443603
Drug interaction 115.28 18.70 27 34761 362056 64101888
Fall 114.54 18.70 41 34747 416785 64047159
Interstitial lung disease 100.23 18.70 185 34603 97547 64366397
Fatigue 99.29 18.70 716 34072 748014 63715930
Metastases to lung 99.00 18.70 75 34713 15189 64448755
Nail toxicity 96.93 18.70 25 34763 331 64463613
Epistaxis 94.72 18.70 181 34607 97950 64365994
Off label use 91.93 18.70 619 34169 632187 63831757
Skin toxicity 88.35 18.70 51 34737 6551 64457393
Dysgeusia 87.32 18.70 117 34671 46930 64417014
Vascular device infection 86.07 18.70 49 34739 6131 64457813
Bone pain 84.79 18.70 116 34672 47456 64416488
Nail dystrophy 84.70 18.70 27 34761 786 64463158
Lymphoedema 83.32 18.70 57 34731 9848 64454096
Product dose omission issue 82.00 18.70 6 34782 194741 64269203
Nausea 81.86 18.70 711 34077 785089 63678855
Hypokalaemia 80.81 18.70 193 34595 121710 64342234
Metastases to liver 80.71 18.70 81 34707 23860 64440084
Nail discolouration 77.10 18.70 34 34754 2466 64461478
Onycholysis 76.86 18.70 30 34758 1596 64462348
Vomiting 76.30 18.70 533 34255 550584 63913360
Pneumonitis 73.93 18.70 112 34676 50253 64413691
Nail disorder 73.42 18.70 50 34738 8574 64455370
Cardiac dysfunction 73.07 18.70 35 34753 3071 64460873
Cardiomyopathy 71.54 18.70 78 34710 25278 64438666
Toxicity to various agents 70.17 18.70 56 34732 363457 64100487
Decreased appetite 69.45 18.70 318 34470 280971 64182973
Lacrimation increased 69.18 18.70 66 34722 18280 64445664
Breast pain 65.06 18.70 43 34745 7018 64456926
Tonsillar disorder 63.84 18.70 23 34765 978 64462966
Drug hypersensitivity 62.54 18.70 25 34763 237790 64226154
Erysipelas 59.72 18.70 45 34743 9036 64454908
Condition aggravated 59.47 18.70 68 34720 372358 64091586
Joint swelling 59.38 18.70 21 34767 215361 64248583
Constipation 59.37 18.70 263 34525 229074 64234870
Drug abuse 58.96 18.70 3 34785 132371 64331573
Cellulitis 57.49 18.70 144 34644 93513 64370431
Confusional state 57.28 18.70 35 34753 261109 64202835
Device related infection 56.57 18.70 76 34712 30550 64433394
Metastasis 55.69 18.70 36 34752 5659 64458285
Lower respiratory tract infection 54.47 18.70 142 34646 94472 64369472
Radiation skin injury 54.04 18.70 22 34766 1308 64462636
Arthropathy 53.06 18.70 3 34785 120964 64342980
Mastectomy 52.46 18.70 20 34768 998 64462946
Mastitis 52.08 18.70 24 34764 1930 64462014
Breast cancer recurrent 51.49 18.70 26 34762 2557 64461387
Infusion related reaction 50.67 18.70 199 34589 164268 64299676
Breast cancer metastatic 50.45 18.70 37 34751 7132 64456812
Therapeutic product effect decreased 50.17 18.70 3 34785 115348 64348596
Myocardial infarction 49.56 18.70 14 34774 165807 64298137
Pleural effusion 49.03 18.70 165 34623 126394 64337550
Neoplasm progression 49 18.70 83 34705 40881 64423063
Metastases to lymph nodes 48.23 18.70 39 34749 8678 64455266
Drug intolerance 47.42 18.70 21 34767 187971 64275973
Bradycardia 46.08 18.70 5 34783 118214 64345730
Onychalgia 45.95 18.70 17 34771 780 64463164
Pseudocirrhosis 45.61 18.70 16 34772 629 64463315
Madarosis 45.12 18.70 23 34765 2307 64461637
Cystitis noninfective 43.93 18.70 18 34770 1088 64462856
Cardiac failure 43.91 18.70 164 34624 132209 64331735
Tumour pain 43.11 18.70 21 34767 1912 64462032
Hyperkalaemia 42.88 18.70 3 34785 101126 64362818
Injection site pain 42.70 18.70 5 34783 111403 64352541
Paraesthesia 42.42 18.70 164 34624 134358 64329586
Carbohydrate antigen 15-3 increased 42.42 18.70 17 34771 970 64462974
Excessive eye blinking 41.66 18.70 18 34770 1242 64462702
Aortitis 40.62 18.70 17 34771 1084 64462860
Abdominal discomfort 40.57 18.70 24 34764 182298 64281646
Nasal disorder 40.52 18.70 23 34765 2861 64461083
Red cell distribution width increased 40.30 18.70 41 34747 12268 64451676
Gastrointestinal haemorrhage 39.85 18.70 11 34777 132301 64331643
Vessel puncture site bruise 39.76 18.70 13 34775 411 64463533
Product use in unapproved indication 39.65 18.70 23 34765 176595 64287349
Musculoskeletal stiffness 39.51 18.70 9 34779 123197 64340747
Meibomian gland dysfunction 39.08 18.70 10 34778 128 64463816
Hyperfibrinogenaemia 38.78 18.70 9 34779 74 64463870
Dyspnoea 38.69 18.70 572 34216 718102 63745842
Gastrointestinal toxicity 38.66 18.70 28 34760 5294 64458650
Somnolence 38.46 18.70 32 34756 203613 64260331
Inappropriate schedule of product administration 38.38 18.70 3 34785 92283 64371661
Hot flush 38.23 18.70 80 34708 46155 64417789
Rhabdomyolysis 38.10 18.70 3 34785 91723 64372221
Dehydration 38.08 18.70 223 34565 216540 64247404
Hypertransaminasaemia 37.32 18.70 31 34757 7160 64456784
Urinary tract infection 36.71 18.70 232 34556 231364 64232580
Gait disturbance 36.45 18.70 24 34764 172131 64291813
White blood cell count abnormal 36.31 18.70 26 34762 4828 64459116
Hyperpyrexia 35.27 18.70 26 34762 5051 64458893
Dry skin 34.94 18.70 82 34706 51079 64412865
Vascular fragility 34.77 18.70 9 34779 121 64463823
Chest discomfort 34.54 18.70 139 34649 115967 64347977
Hypoglycaemia 34.53 18.70 4 34784 89888 64374056
Cardio-respiratory arrest 34.02 18.70 6 34782 98387 64365557
Blood creatine increased 33.82 18.70 31 34757 8161 64455783
Biliary sepsis 33.31 18.70 16 34772 1412 64462532
Depressed level of consciousness 32.90 18.70 3 34785 81433 64382511
Colitis 32.67 18.70 87 34701 58587 64405357
Post-traumatic pain 32.36 18.70 11 34777 393 64463551
Anaemia 32.32 18.70 329 34459 378351 64085593
Alopecia areata 32.28 18.70 16 34772 1512 64462432
Nail infection 32.23 18.70 17 34771 1830 64462114
Hepatic enzyme increased 32.01 18.70 15 34773 129928 64334016
Paronychia 31.66 18.70 27 34761 6465 64457479
Acute interstitial pneumonitis 31.51 18.70 14 34774 1033 64462911
Rhinorrhoea 31.47 18.70 87 34701 59882 64404062
Hypoaesthesia 31.14 18.70 153 34635 138955 64324989
Nail bed bleeding 30.71 18.70 10 34778 312 64463632
Dyspepsia 30.46 18.70 104 34684 80208 64383736
Metastases to skin 30.07 18.70 15 34773 1437 64462507
Sinusitis 30.01 18.70 21 34767 145907 64318037
Hepatic lesion 30.01 18.70 25 34763 5799 64458145
Hair texture abnormal 29.40 18.70 19 34769 2985 64460959
Vaginal prolapse 28.73 18.70 9 34779 247 64463697
Exposure during pregnancy 28.52 18.70 4 34784 77671 64386273
Hypothalamo-pituitary disorder 28.38 18.70 13 34775 1031 64462913
HER2 positive breast cancer 28.36 18.70 9 34779 258 64463686
Folate deficiency 28.34 18.70 18 34770 2745 64461199
Osteitis condensans 28.26 18.70 6 34782 31 64463913
Neurotoxicity 28.21 18.70 52 34736 27352 64436592
Mobility decreased 28.06 18.70 6 34782 85834 64378110
Metastases to meninges 28.03 18.70 18 34770 2797 64461147
Overdose 27.81 18.70 27 34761 159539 64304405
Feeling abnormal 27.77 18.70 19 34769 133583 64330361
Pituitary tumour 27.66 18.70 13 34775 1093 64462851
Axillary pain 27.58 18.70 15 34773 1717 64462227
Pyrexia 27.43 18.70 438 34350 558206 63905738
Skin infection 27.28 18.70 37 34751 15000 64448944
Arthritis 27.11 18.70 6 34782 83808 64380136
Renal impairment 27.02 18.70 20 34768 134997 64328947
Therapeutic product effect incomplete 26.98 18.70 11 34777 103471 64360473
Tongue coated 26.96 18.70 13 34775 1157 64462787
Cardiac arrest 26.93 18.70 26 34762 154038 64309906
Delirium 26.78 18.70 3 34785 69191 64394753
Haemorrhoids 26.57 18.70 47 34741 23954 64439990
Onychoclasis 26.37 18.70 21 34767 4571 64459373
Breast inflammation 26.15 18.70 7 34781 108 64463836
Hallucination 26.14 18.70 4 34784 72784 64391160
Systolic dysfunction 25.92 18.70 18 34770 3184 64460760
Hair colour changes 25.69 18.70 19 34769 3708 64460236
Pain 25.68 18.70 184 34604 553327 63910617
Osteolysis 25.65 18.70 17 34771 2786 64461158
Cerebrovascular accident 25.50 18.70 22 34766 137561 64326383
Pulmonary hypoplasia 25.47 18.70 6 34782 53 64463891
Suicidal ideation 25.46 18.70 3 34785 66539 64397405
Enterocolitis infectious 25.14 18.70 16 34772 2448 64461496
Coma 25.07 18.70 8 34780 87607 64376337
Blood magnesium decreased 24.90 18.70 34 34754 13871 64450073
Mean platelet volume decreased 24.84 18.70 14 34774 1717 64462227
Catheter site pain 24.76 18.70 20 34768 4442 64459502
Therapy partial responder 24.61 18.70 29 34759 10219 64453725
Osteosclerosis 24.55 18.70 18 34770 3468 64460476
Gastritis 24.55 18.70 64 34724 42554 64421390
Hyperchlorhydria 24.34 18.70 14 34774 1785 64462159
Systemic lupus erythematosus 24.22 18.70 6 34782 77606 64386338
Perforation 24.19 18.70 12 34776 1136 64462808
Osteonecrosis of jaw 24.17 18.70 61 34727 39764 64424180
Tidal volume decreased 24.04 18.70 6 34782 69 64463875
Metastases to spine 23.84 18.70 18 34770 3625 64460319
Urinary tract disorder 23.78 18.70 17 34771 3149 64460795
Agitation 23.68 18.70 9 34779 88358 64375586
Keratitis 23.44 18.70 17 34771 3220 64460724
Onychomadesis 22.85 18.70 16 34772 2868 64461076
Dental fistula 22.74 18.70 9 34779 497 64463447
Odynophagia 22.68 18.70 27 34761 9614 64454330
Treatment failure 22.48 18.70 18 34770 116798 64347146
Coronary artery disease 22.45 18.70 3 34785 60430 64403514
Palmar erythema 22.32 18.70 13 34775 1697 64462247
Postural orthostatic tachycardia syndrome 22.23 18.70 9 34779 527 64463417
Back pain 22.10 18.70 219 34569 249952 64213992
Nasal congestion 22.07 18.70 3 34785 59655 64404289
Sarcoid-like reaction 22.06 18.70 4 34784 7 64463937
Pneumonitis chemical 22.01 18.70 8 34780 349 64463595
Asthma 21.94 18.70 12 34776 95213 64368731
Blood glucose increased 21.68 18.70 13 34775 98060 64365884
Osteoarthritis 21.60 18.70 4 34784 63332 64400612
Electrocardiogram QT prolonged 21.44 18.70 8 34780 79440 64384504
Respiratory tract infection 21.36 18.70 56 34732 37351 64426593
Renal failure 21.32 18.70 41 34747 181647 64282297
Metastases to soft tissue 21.28 18.70 8 34780 384 64463560
Weight increased 21.04 18.70 53 34735 213295 64250649
Flushing 20.91 18.70 91 34697 78557 64385387
Influenza like illness 20.90 18.70 77 34711 61625 64402319
Paralysis recurrent laryngeal nerve 20.86 18.70 6 34782 122 64463822
Dandy-Walker syndrome 20.85 18.70 5 34783 48 64463896
Subcutaneous abscess 20.42 18.70 22 34766 7031 64456913
Borrelia infection 20.33 18.70 6 34782 134 64463810
Corneal disorder 20.28 18.70 13 34775 2014 64461930
Disorientation 20.20 18.70 3 34785 55825 64408119
Dysuria 20.10 18.70 59 34729 41998 64421946
Mucosal dryness 20.02 18.70 15 34773 2986 64460958
Appendiceal abscess 19.96 18.70 7 34781 275 64463669
Spinal pain 19.84 18.70 29 34759 12592 64451352
Myalgia 19.84 18.70 150 34638 158467 64305477
Product use issue 19.82 18.70 32 34756 151683 64312261
Pleural disorder 19.54 18.70 9 34779 723 64463221
Enterocolitis 19.46 18.70 28 34760 11990 64451954
Rectal haemorrhage 19.17 18.70 75 34713 61742 64402202
Discomfort 18.91 18.70 10 34778 80868 64383076
Nail bed tenderness 18.80 18.70 7 34781 327 64463617
Wheezing 18.78 18.70 10 34778 80569 64383375
Urogenital prolapse 18.78 18.70 4 34784 21 64463923

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FD02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
ATC L01XY02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Combinations of antineoplastic agents
FDA MoA N0000020008 HER2/Neu/cerbB2 Antagonists
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
FDA EPC N0000175661 HER2/neu Receptor Antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
HER2-positive carcinoma of breast indication 427685000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Receptor tyrosine-protein kinase erbB-2 Kinase ANTIBODY BINDING UNKNOWN DRUG LABEL

External reference:

IDSource
D05446 KEGG_DRUG
4031566 VUID
N0000185031 NUI
4031566 VANDF
CHEMBL2007641 ChEMBL_ID
C485206 MESH_SUPPLEMENTAL_RECORD_UI
5046 IUPHAR_LIGAND_ID
8380 INN_ID
DB06366 DRUGBANK_ID
K16AIQ8CTM UNII
1298944 RXNORM
190566 MMSL
28589 MMSL
d07874 MMSL
704226002 SNOMEDCT_US
704227006 SNOMEDCT_US
C1328025 UMLSCUI
014427 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PERJETA HUMAN PRESCRIPTION DRUG LABEL 1 50242-145 INJECTION, SOLUTION, CONCENTRATE 30 mg INTRAVENOUS BLA 31 sections
Phesgo HUMAN PRESCRIPTION DRUG LABEL 3 50242-245 INJECTION, SOLUTION 1200 mg SUBCUTANEOUS BLA 30 sections
Phesgo HUMAN PRESCRIPTION DRUG LABEL 3 50242-260 INJECTION, SOLUTION 600 mg SUBCUTANEOUS BLA 30 sections